191 related articles for article (PubMed ID: 33843403)
1. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Walker KL; Rinella SP; Hess NJ; Turicek DP; Kabakov SA; Zhu F; Bouchlaka MN; Olson SL; Cho MM; Quamine AE; Feils AS; Gavcovich TB; Rui L; Capitini CM
Leuk Lymphoma; 2021 May; 62(5):1167-1177. PubMed ID: 33843403
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
3. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
[TBL] [Abstract][Full Text] [Related]
4. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
5. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients.
Davis JE; Du K; Ludford-Menting MJ; Prabahran A; Wong E; Huntington ND; Koldej RM; Ritchie DS
Front Immunol; 2021; 12():749094. PubMed ID: 34630428
[TBL] [Abstract][Full Text] [Related]
7. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
8. Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.
Li D; Yuan Y; Meng C; Lin Z; Zhao M; Shi L; Li M; Ye D; Cai Y; He X; Ye H; Zhou S; Zhou H; Gao S
Clin Epigenetics; 2024 Mar; 16(1):48. PubMed ID: 38528641
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
10. Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia.
Jost TR; Borga C; Radaelli E; Romagnani A; Perruzza L; Omodho L; Cazzaniga G; Biondi A; Indraccolo S; Thelen M; Te Kronnie G; Grassi F
J Leukoc Biol; 2016 Jun; 99(6):1077-87. PubMed ID: 26931577
[TBL] [Abstract][Full Text] [Related]
11. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
12. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
13. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
14. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Yu X; Munoz-Sagredo L; Streule K; Muschong P; Bayer E; Walter RJ; Gutjahr JC; Greil R; Concha ML; Müller-Tidow C; Hartmann TN; Orian-Rousseau V
Blood; 2021 Sep; 138(12):1067-1080. PubMed ID: 34115113
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
[TBL] [Abstract][Full Text] [Related]
17. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
[TBL] [Abstract][Full Text] [Related]
18. PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.
Müller TA; Pennisi S; Zwick A; Decker S; Klein C; Rister B; Rudorf A; Kissel S; Follo M; Wäsch R; Illert AL; Pfeifer D; Oostendorp R; Waskow C; Dierks C; Duyster J
Leukemia; 2019 May; 33(5):1296-1301. PubMed ID: 30816332
[No Abstract] [Full Text] [Related]
19. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
20. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
